Seymour JF, Kipps TJ, Eichhorst B, et al. MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting and Exposition 2018, abstract 184.
Derde generatie anti-CD19 CAR T-cellen voor gerecidiveerde/refractaire CLL
jan 2025 | Leukemie, Lymfoom